Overview of alemtuzumab therapy for the treatment of T-cell lymphomas

References

• Hale G, Xia MQ, Tighe HP, . The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118–127.
   PubMed Web of Science ®Google Scholar
• Xia MQ, Hale G, Lifely MR, . Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293:633–640.
   PubMed Web of Science ®Google Scholar
• Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988;18:1507–1514.
   PubMed Web of Science ®Google Scholar
• Osterborg A, Foà R, Bezares RF, . Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009;23:1980–1988.
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E, . Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185–191.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E, . Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998;92:76–82.
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M, . A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920–2924.
   PubMed Web of Science ®Google Scholar
• Lundin J, Hagberg H, Repp R, . Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267–4272.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Patti C, . Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110: 2316–2323.
   PubMed Web of Science ®Google Scholar
• Went P, Agostinelli C, Gallamini A, . Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006;24:2472–2479.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Abramson JS, Pinkus GS, . Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174–7179.
   PubMed Web of Science ®Google Scholar
• Chang ST, Lu CL, Chuang SS. CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma 2007;48:117–121.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Agostinelli C, Righi S, . Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007;92:566–567.
   PubMed Web of Science ®Google Scholar
• Jiang L, Yuan CM, Hubacheck J, . Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol 2009;145:173–179.
   PubMed Web of Science ®Google Scholar
• Geissinger E, Bonzheim I, Roth S, . CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk Lymphoma 2009;50:1010–1016.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Alinari L, Tani M, . Preliminary observation of a phase II study of reduced-dose alemtuzumab in patients with pretreated T-cell lymphoma. Haematologica 2005;90:702–703.
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chae YS, . Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007;60:129–134.
   PubMed Web of Science ®Google Scholar
• Binder C, Ziepert M, Loeffler M, . Final analysis of phase II study of CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1). Blood 2007;110(Suppl. 1): Abstract 3431.
   PubMed Web of Science ®Google Scholar
• Intragumtonchai T, Bunworasate U, Nakorn TN, . Alemtuzumab in combination with CHOP and ESHAP as first-line treatment in peripheral T-cell lymphoma. Blood 2006;108(Suppl. 1): Abstract 4740.
   Google Scholar
• Janik JE, Dunleavy K, Pittaluga S, . A pilot trial of Campath-1H and dose-adjusted EPOCH in CD52-expressing aggressive T-cell malignancies. Blood 2005;106(Suppl. 1): Abstract 3348.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, . Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Ann Oncol 2009;20:390–392.
   PubMed Web of Science ®Google Scholar
• Kuan JW, Lau NS, Chang KM, . Experience in using HyperCVAD combined with alemtuzumab in treating peripheral T-cell and T/NK cell neoplasms. Blood 2008;112(Suppl. 1): Abstract 5013.
   Google Scholar
• Ravandi F, Aribi A, O'Brien S, . Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 2009;27:5425–5430.
   PubMed Web of Science ®Google Scholar
• Sharma K, Janik JE, O'Mahony D, . Alemtuzumab (Camapth-1H) in patients with HTLV1-asociated adult T-cell leukemia/lymphoma. Blood 2008;112(Suppl. 1); Abstract 2010.
   Google Scholar
• Weidmann E, Hess G, Chow KU, . A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma 2010;51:447–455.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Coenen JL, Boers JE, . EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 2008;112:1039–1041.
   PubMed Web of Science ®Google Scholar
• Senff NJ, Noordijk EM, Kim YH, . European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphomas consensus recommendations for the management of cutaneous B-Cell lymphomas. Blood 2008;112:1600–1609.
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Marsden JR, Spittle M, . British Association of Dermatologists; UK Cutaneous Lymphoma Group. Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group Guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003;149:1095–1107.
   PubMed Web of Science ®Google Scholar
• Willemze R, Dreyling M. Primary cutaneous lymphomas: ESMO clinical recommendations for diagnosis, treatment, and follow-up. Ann Oncol 2010;21(Suppl. 5):v177–v180.
   Google Scholar
• National Comprehensive Cancer Network Guidelines 2009.
   Google Scholar
• Alinari L, Geskin L, Grady T, . Subcutaneous alemtuzumab for Sezary syndrome in the very elderly. Leuk Res 2008;32:1299–1303.
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Seymour JF, Wolf M, . Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haemtol 2003;71:250–256.
   PubMed Web of Science ®Google Scholar
• Bernengo MG, Quaglino P, Comessatti A, . Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007;92:784–794.
   PubMed Web of Science ®Google Scholar
• Beltran-Garate B, Gomez H, Lopez JL, . Alemtuzumab in patients with advanced mycosis fungoides and Sezary syndrome. Blood 2007;110(Suppl. 1): Abstract 3425.
   Google Scholar
• Fisher DC, Tawa M, Walsh M, . Low-dose alemtuzumab is uniquely effective in refractory leukemic cutaneous T cell lymphoma (L-CTCL). Blood 2009;114(Suppl. 1): Abstract 3748.
   Google Scholar
• Lenihan DJ, Alencar AJ, Yang D, . Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004;104:65–68.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Mehta N, Rosen ST, . Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 2009;50:1969–1976.
   PubMed Web of Science ®Google Scholar
• Rupoli S, Goteri G, Picardi P, . Alemtuzumab in combination with interferon or gemcitabine in aggressive and advanced cutaneous T-cell lymphomas: report of preliminary results. Blood 2008;112(Suppl. 1): Abstract 5000.
   Google Scholar
• Lundin J, Kimby E, Björkholm M, . A phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768–773.
   PubMed Web of Science ®Google Scholar
• Karlsson C, Lundin J, Kimby E, . Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 2009;144:78–85.
   PubMed Web of Science ®Google Scholar
• Hale G, Rebello P, Brettman LR, . Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104:948–955.
   PubMed Web of Science ®Google Scholar
• Gibbs SD, Westerman DA, McCormack C, . Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol 2005;130:87–91.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Ravandi F, Riehl T, . Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008;111:1816–1819.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006;7:125–130.
   PubMedGoogle Scholar
• Osterborg A, Foà R, Bezares RF, . Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009;11:1980–1988.
   Web of Science ®Google Scholar
• Sohani AR, Ferry JA, Chang PS, . Epstein-Barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. J Clin Oncol 2010;28:e69–e72.
   PubMed Web of Science ®Google Scholar
• Thursky KA, Worth LJ, Seymour JF, . Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006;132:3–12.
   PubMed Web of Science ®Google Scholar
• Martin SI, Marty FM, Fiumara K, . Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16–24.
   PubMed Web of Science ®Google Scholar
• Lundin J, Kennedy B, Dearden C, . No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. Blood 2005;105:4148–4149.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Pro B, Pinter-Brown L, . Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182–1189.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, . Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. Blood 2010;116(Suppl. 1): Abstract 114.
   Google Scholar